Get the Stockscreener App
15.25
0.53%
0.08
Pre-market:
15.28
0.03
+0.20%
Corvus Pharmaceuticals Inc stock is traded at $15.25, with a volume of 1.21M.
It is up +0.53% in the last 24 hours and down -0.46% over the past month.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
See More
Previous Close:
$15.17
Open:
$15.21
24h Volume:
1.21M
Relative Volume:
0.38
Market Cap:
$1.28B
Revenue:
-
Net Income/Loss:
$-15.28M
P/E Ratio:
-30.13
EPS:
-0.5061
Net Cash Flow:
$-32.97M
1W Performance:
+6.27%
1M Performance:
-0.46%
6M Performance:
+116.62%
1Y Performance:
+403.30%
1-Day Range:
$15.00
$16.09
1-Week Range:
$14.73
$16.09
52-Week Range:
$3.02
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.25 | 1.27B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Price Action: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Aug Drivers: What are the risks of holding Corvus Pharmaceuticals Inc2026 Setups & High Accuracy Swing Trade Signals - baoquankhu1.vn
Investment Review: Is Corvus Pharmaceuticals Inc a stock for growth or value investors - baoquankhu1.vn
Growth Recap: Will Corvus Pharmaceuticals Inc outperform during market rallies2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success - Seeking Alpha
What analysts say about Corvus Pharmaceuticals Inc stockBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Fed Watch: Will Corvus Pharmaceuticals Inc benefit from green energy policies2026 Big Picture & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving AverageWhat's Next? - marketbeat.com
Market Review: How cyclical is Corvus Pharmaceuticals Incs revenue streamWeekly Profit Analysis & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Corvus Pharmaceuticals, Inc. (CRVS) Options Chain - Yahoo! Finance Canada
CRVS Should I Buy - Intellectia AI
Vanguard amends ownership for Corvus Pharmaceuticals (NASDAQ: CRVS) after realignment - Stock Titan
Corvus leads drug developers as index climbs in early 2026 - BioWorld MedTech
Earnings Beat: Is Corvus Pharmaceuticals Inc undervalued by DCF analysisTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Movement Recap: What analysts say about Corvus Pharmaceuticals Inc stock - baoquankhu1.vn
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 8.4% HigherTime to Buy? - MarketBeat
Corvus Ignites: A 9.73% Surge Shakes the Market, But What Fuels the Flame? - Bitget
Income Plays: Can Corvus Pharmaceuticals Inc beat the S P 5002026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Is Corvus Pharmaceuticals Inc forming a breakout pattern2026 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - MSN
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS? - Sahm
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Growth Recap: Will Corvus Pharmaceuticals Inc outperform tech stocksEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings - Sahm
FY2030 Earnings Forecast for CRVS Issued By HC Wainwright - MarketBeat
Corvus outlines cash runway into Q2 2028 and targets mid-2027 Phase II readout for soquelitinib in atopic dermatitis - MSN
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - Sahm
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million - The Globe and Mail
Oppenheimer Remains a Buy on Corvus Pharmaceuticals (CRVS) - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline - TipRanks
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss - MarketBeat
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program - Stock Titan
Corvus Pharmaceuticals (NASDAQ: CRVS) doubles Jefferies ATM capacity to $200M - Stock Titan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com South Africa
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):